An exploratory comparative analysis of tyrosine kinase inhibitors or docetaxel in second-line treatment of EGFR wild-type non-small-cell lung cancer: a retrospective real-world practice review at a single tertiary care centre

BACKGROUND: Treatment for advanced non-small-cell lung cancer (nsclc), especially in patients with wild-type EGFR, remains limited. Recently, erlotinib, a tyrosine kinase inhibitor (tki) targeting EGFR mutation, was approved as second-line treatment in EGFR wild-type nsclc. Despite evidence of bette...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Curr Oncol
Päätekijät: Ma, K., Cohen, V., Kasymjanova, G., Small, D., Novac, K., Peterson, J., Levit, A., Agulnik, J.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Multimed Inc. 2015
Aiheet:
Original Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4462537/
https://ncbi.nlm.nih.gov/pubmed/26089726
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.22.2296
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia